by Stacey Johnson | Mar 22, 2013
Signals Blog has given itself the green light to try something different. We’re launching a brand new feature, to appear on Fridays, which will showcase the “lighter” side of regenerative medicine. We will be bringing you cartoons, photos, videos and other content...
by David Brindley | Mar 19, 2013
. Part 5 in Cell Therapy Industry 2027 series A short time ago, I had the immense pleasure of driving through the Napa Valley bathed in a warm pastel sunset. The view was accompanied by a two-chord soundtrack: the reassuring chinking of several bottles of the...
by Paul Krzyzanowski | Mar 16, 2013
. As a follow up to last month’s post describing how leaked information about an Alzheimer’s drug clinical trial led to the largest ever case of insider trading and destroyed the careers of Dr. Sidney Gilman, a well-respected clinician, and Matthew Martoma, a young...
by Paul Krzyzanowski | Mar 13, 2013
[pullquote]In time, this purchase might make BioTime the company that Geron was supposed to be.[/pullquote]Avid watchers of the stem cell and regenerative medicine market have no doubt heard of Geron selling its stem cell assets to BioTime. Nature covered it in some...
by Natasha Davie | Mar 5, 2013
When it comes to the cell therapy commercialization crunch there are some fundamental questions that need to be answered. Is your product going to be frozen or fresh? How will the product be administered? What is your dosing strategy? And the one that I’m going to...
by Ubaka Ogbogu | Feb 26, 2013
Patients contemplating medical travel for the purpose of receiving scientifically unproven stem cell treatments may wish to consider one more potential side effect: the possibility of losing their eligibility for health status-related compensation and benefits. In May...
by Nick Dragojlovic | Feb 20, 2013
– The regenerative medicine community greeted last month’s decision by the U.S. Supreme Court to uphold the legality of the Obama Administration’s stem cell policy with relief. The court found that federal funding of human embryonic stem cell (hESC) research is...
by Paul Krzyzanowski | Feb 14, 2013
– Nature kicked off 2013 with an unsettling article about how privileged information from research studies is being used to garner gigantic returns for investors, large and small. It’s not surprising, considering that one of the most egregious cases of so called...
by Roshan Yoganathan | Feb 12, 2013
Only in the fictional land of Oz does water cause witches to melt. In the real world, water is essential to life and a valuable resource. Scientifically known as H2O, it is used to irrigate crops and even to enlarge/swell biomaterial gels (more on that later). As a...
by David Kent | Feb 8, 2013
Previous posts from Angela and Michelle will have alerted readers to the importance of where a stem cell resides in the body. The stem cell niche is a complicated environment and one of the most challenging things for blood stem cell biologists to decipher is how...
Comments